The Inflation Reduction Act’s attempt to improve insulin costs for Medicare beneficiaries-by capping out-of-pocket costs at $35-was associated with lower out-of-pocket costs and increased insulin usage, but only for a small portion of U.S. patients, according to a new study published in JAMA on Saturday.